Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 3
1990 1
1991 3
1992 1
1993 3
1994 3
1995 1
1996 2
1997 3
1998 5
1999 1
2000 2
2001 2
2002 2
2003 3
2004 4
2005 3
2006 3
2007 5
2008 1
2009 9
2010 9
2011 8
2012 8
2013 12
2014 4
2015 5
2016 9
2017 7
2018 3
2019 4
2020 2
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

120 results
Results by year
Filters applied: . Clear all
Page 1
[Adverse reactions to anti-hormonal therapy affects adherence].
von Wachenfeldt A, Andersson A, Fornander T, Isaksson Friman E, Johnsson A, Uddbom E, Uttermalm AC. von Wachenfeldt A, et al. Among authors: fornander t. Lakartidningen. 2017 Feb 14;114:EED7. Lakartidningen. 2017. PMID: 28221399 Free article. Swedish. No abstract available.
IP6K2 predicts favorable clinical outcome of primary breast cancer.
Sandström J, Balian A, Lockowandt R, Fornander T, Nordenskjöld B, Lindström L, Pérez-Tenorio G, Stål O. Sandström J, et al. Among authors: fornander t. Mol Clin Oncol. 2021 May;14(5):94. doi: 10.3892/mco.2021.2256. Epub 2021 Mar 12. Mol Clin Oncol. 2021. PMID: 33767863 Free PMC article.
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ. Løkkegaard S, et al. Among authors: fornander t. NPJ Breast Cancer. 2021 Jan 4;7(1):2. doi: 10.1038/s41523-020-00210-8. NPJ Breast Cancer. 2021. PMID: 33398005 Free PMC article.
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ; STO Trialists Group. Lindström LS, et al. Among authors: fornander t. J Natl Cancer Inst. 2018 Jul 1;110(7):726-733. doi: 10.1093/jnci/djx270. J Natl Cancer Inst. 2018. PMID: 29361175 Free PMC article.
Adjuvant docetaxel for node-positive breast cancer.
Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Martin M, et al. Among authors: fornander t. N Engl J Med. 2005 Jun 2;352(22):2302-13. doi: 10.1056/NEJMoa043681. N Engl J Med. 2005. PMID: 15930421 Free article. Clinical Trial.
VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA. Aguilar H, et al. Among authors: fornander t. Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664. Breast Cancer Res. 2014. PMID: 24886537 Free PMC article.
120 results